Management of Thromboembolism in Hematologic Malignancies

 

 Buy Article Permissions and Reprints

ABSTRACT

Patients with hematologic malignancies have increased risks of thromboembolism or bleeding. The commonest thrombotic complication is venous thromboembolism (VTE). Other thrombotic conditions occur in association with specific disorders, such as thrombotic thrombocytopenic purpura in hematopoietic stem cell transplantation and disseminated intravascular coagulation in acute promyelocytic leukemia. Clinical trials show that unfractionated heparin (UFH) and low molecular weight heparin (LMWH) are efficacious for VTE prophylaxis in cancer patients after major surgery or when hospitalized for acute medical illnesses. These findings in cancer patients are probably applicable to patients with hematologic malignancies, in whom there are very few studies. However, the effectiveness of anticoagulant VTE prophylaxis is not established in ambulatory patients with cancer except for multiple myeloma patients treated with thalidomide and chemotherapy. LMWH is widely used as initial treatment for VTE because it enables home therapy without laboratory monitoring, thereby improving the patient's quality of life. UFH is preferred in patients with high bleeding risks and renal impairment. In cancer patients, vitamin K antagonists for the long-term treatment of VTE are increasingly replaced by LMWH, which show superior efficacy. When prescribing anticoagulant prophylaxis or treatment to patients with hematologic malignancies, clinical benefits must be weighed carefully against the risks of bleeding.

REFERENCES

• 1 Trousseau A. Phlegmasia alba dolens. Clinique Medicale de l'Hotel-Dieu de Paris.  The New Sydenham Society. 1865;  3 94-99
  PubMedGoogle Scholar
• 2 Ottinger H, Belka C, Kozole G et al.. Deep venous thrombosis and pulmonary artery embolism in high-grade non-Hodgkin's lymphoma: incidence, causes and prognostic relevance.  Eur J Haematol. 1995;  54 186-194
  CrossrefPubMedGoogle Scholar
• 3 Gugliotta L, Mazzucconi M G, Leone G et al.. Incidence of thrombotic complications in adult patients with acute lymphoblastic leukemia receiving L-asparaginase during induction therapy: a retrospective study. The GIMEMA Group.  Eur J Haematol. 1992;  49 63-66
  CrossrefPubMedGoogle Scholar
• 4 Zangari M, Barlogie B, Anaissie E et al.. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.  Br J Haematol. 2004;  126 715-721
  CrossrefPubMedGoogle Scholar
• 5 Zangari M, Anaissie E, Barlogie B et al.. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.  Blood. 2001;  98 1614-1615
  CrossrefPubMedGoogle Scholar
• 6 Mitchell L G, Andrew M, Hanna K et al.. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving L-asparaginase for acute lymphoblastic leukemia. Results of the PARKAA study.  Thromb Haemost. 2003;  90 235-244
  PubMedGoogle Scholar
• 7 Athale U H, Chan A KC. Thrombosis in children with acute lymphoblastic leukemia Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia; effects of the disease and therapy.  Thromb Res. 2003;  111 199-212
  CrossrefPubMedGoogle Scholar
• 8 Sanz M A, Tallman M S, Le-Coco F. Practice points, consensus, and controversial issues in the management of patients with newly diagnosed acute promyelocytic leukemia.  Oncologist. 2005;  10 806-814
  CrossrefPubMedGoogle Scholar
• 9 Barbui T, Finazzi G, Falanga A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia.  Blood. 1998;  91 3093-3102
  PubMedGoogle Scholar
• 10 Uderzo C, Fumagalli M, de Lorenzo P et al.. Impact of thrombotic thrombocytopenic purpura on leukemic children undergoing bone marrow transplantation.  Bone Marrow Transplant. 2000;  26 1005-1009
  CrossrefPubMedGoogle Scholar
• 11 Alessandrino E P, Martinelli G, Canevari A et al.. Prompt response to high-dose intravenous immunoglobulins given as first-line therapy in post-transplant thrombotic thrombocytopenic purpura.  Bone Marrow Transplant. 2000;  25 1217-1218
  CrossrefPubMedGoogle Scholar
• 12 Rosovsky R P, Kuter D J. Catheter-related thrombosis in cancer patients: pathophysiology, diagnosis, and management.  Hematol Oncol Clin North Am. 2005;  19 183-202
  CrossrefPubMedGoogle Scholar
• 13 De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms.  Crit Rev Oncol Hematol. 2004;  50 187-196
  PubMedGoogle Scholar
• 14 Falanga A, Gordon S G. Isolation and characterisation of cancer procoagulant: a cysteine proteinase from malignant tissue.  Biochemistry. 1985;  24 5558-5567
  CrossrefPubMedGoogle Scholar
• 15 Falanga A, Consonni R, Marchetti M et al.. Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by retinoic acid.  Leukemia. 1994;  8 156-159
  PubMedGoogle Scholar
• 16 Rickles F R, Falanga A. Molecular basis for the relationship between thrombosis and cancer.  Thromb Res. 2001;  102 V215-V224
  CrossrefPubMedGoogle Scholar
• 17 Morel O, Toti F, Hugel B, Freyssinet J M. Cellular microparticles: a disseminated storage pool of bioactive vascular effectors.  Curr Opin Hematol. 2004;  11 156-164
  CrossrefPubMedGoogle Scholar
• 18 Sase T, Wada H, Yamaguchi M et al.. Haemostatic abnormalities and thrombotic disorders in malignant lymphoma.  Thromb Haemost. 2005;  93 153-159
  PubMedGoogle Scholar
• 19 Dixit A, Kannan M, Mahapatra M, Choudhry V P, Saxena R. Roles of protein C, protein S, and antithrombin III in acute leukemia.  Am J Hematol. 2006;  81 171-174
  CrossrefPubMedGoogle Scholar
• 20 Athale U H, Chan A KC. Thrombosis in children with acute lymphoblastic leukemia Part I. Epidemiology of thrombosis in children with acute lymphoblastic leukemia.  Thromb Res. 2003;  111 125-131
  CrossrefPubMedGoogle Scholar
• 21 Athale U H, Siciliano S A, Crowther M, Barr R D, Chan A K. Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease.  Br J Haematol. 2005;  129 803-810
  CrossrefPubMedGoogle Scholar
• 22 Barbui T, Falanga A. Thalidomide and thrombosis in multiple myeloma.  J Thromb Haemost. 2003;  1 421-422
  CrossrefPubMedGoogle Scholar
• 23 Nowak-Gottl U, Heinecke A, von Kries R et al.. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration.  Thromb Res. 2001;  103 165-172
  CrossrefPubMedGoogle Scholar
• 24 Mauz-Korholz C, Junker R, Gobel U, Nowak-Gottl U. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols).  Thromb Haemost. 2000;  83 840-843
  PubMedGoogle Scholar
• 25 Mitchell L G, Hoogendoorn H, Giles P V, Andrew M. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L-asparaginase-induced anti-thrombin III deficiency.  Blood. 1994;  83 386-391
  PubMedGoogle Scholar
• 26 Mitchell L G, Sutor A N, Andrew M. Hemostasis in childhood acute lymphoblastic leukemia; coagulopathy induced by disease and treatment.  Semin Thromb Hemost. 1995;  21 390-401
  Article in Thieme ConnectPubMedGoogle Scholar
• 27 Semeraro N, Montemurro P, Giordano P et al.. Unbalanced coagulation-fibrinolysis potential during L-asparaginase therapy in children with acute lymphoblastic leukemia.  Thromb Haemost. 1990;  64 38-40
  PubMedGoogle Scholar
• 28 Andrew M, Brooker L, Mitchell L. Acquired antithrombin III deficiency secondary to asparaginase therapy in childhood acute lymphoblastic leukemia.  Blood Coagul Fibrinolysis. 1994;  5 S24-S36
  PubMedGoogle Scholar
• 29 Zaunschirm A, Muntean W. Correction of hemostatic imbalances induced by L-asparaginase therapy in children with acute lymphoblastic leukemia.  Pediatr Hematol Oncol. 1986;  3 19-25
  CrossrefPubMedGoogle Scholar
• 30 Halton J M, Mitchell L G, Vegh P A, Eves M, Andrew M A. Fresh frozen plasma has no beneficial effect on the hemostatic system in children receiving L-asparaginase.  Am J Hematol. 1994;  47 157-161
  CrossrefPubMedGoogle Scholar
• 31 Nowak Gottl U, Rath B, Binder M et al.. Inefficacy of fresh frozen plasma in the treatment of L-asparaginase-induced coagulation factor deficiency during ALL induction therapy.  Haematologica. 1995;  80 451-453
  PubMedGoogle Scholar
• 32 Nowak Gottl U, Kuhn N, Wolff J EA et al.. Inhibition of hypercoagulation by antithrombin substitution in E. coli L-asparaginase treated children.  Eur J Haematol. 1996;  56 35-38
  PubMedGoogle Scholar
• 33 Nowak Gottl U, Weberr G, Ziemann D, Ahlke E, Boos J. Influence of two different E coli asparaginase preparations of fibrinolytic proteins in childhood ALL.  Haematologica. 1996;  81 127-131
  PubMedGoogle Scholar
• 34 Nowak-Gottl U, Ahlke E, Klosel K, Jurgens H, Boos J. Changes in coagulation and fibrinolysis in childhood acute lymphoblastic leukemia re-induction therapy using three different asparaginase preparations.  Eur J Pediatr. 1997;  156 848-850
  CrossrefPubMedGoogle Scholar
• 35 Duval M, Suciu S, Ferster A et al.. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organization for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial.  Blood. 2002;  99 2734-2739
  CrossrefPubMedGoogle Scholar
• 36 Isacson S. The effect of prednisolone on the coagulation and fibrinolytic system.  Scand J Haematol. 1970;  7 212-216
  PubMedGoogle Scholar
• 37 Patrassi G M, Sartori M T, Riggotti P et al.. Reduced fibrinolytic potential one year after kidney transplantation: relationship to long term steroid therapy.  Transplantation. 1995;  59 1416-1420
  CrossrefPubMedGoogle Scholar
• 38 Sutor A H, Niemeyer C, Sauter S et al.. Corticosteroids cause multiple changes of coagulation factors.  Ann Hematol. 1992;  4 A83
  PubMedGoogle Scholar
• 39 Ozturk G, Ozsoylu S, Muriel T. Effects of methylprednisolone on FVIII:c and vWF levels.  Eur J Haematol. 1994;  53 119-120
  PubMedGoogle Scholar
• 40 Scarpace S L, Hahn T, Roy H et al.. Arterial thrombosis in four patients treated with thalidomide.  Leuk Lymphoma. 2005;  46 239-242
  CrossrefPubMedGoogle Scholar
• 41 Osman K, Comenzo R, Rajkumar S V. Deep vein thrombosis and thalidomide therapy for multiple myeloma.  N Engl J Med. 2001;  344 1951-1952
  CrossrefPubMedGoogle Scholar
• 42 Dimopoulos M A, Anagnostopoulos A, Terpos E et al.. Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma.  Haematologica. 2006;  91 252-254
  PubMedGoogle Scholar
• 43 Groopman J, Ellman J. Acute promyelocytic leukemia.  Am J Hematol. 1979;  7 395-408
  CrossrefPubMedGoogle Scholar
• 44 Tallman M S, Kwaan H C. Reasssessing the hemostatic disorder associated with acute promyelocytic leukemia.  Blood. 1992;  79 543-553
  PubMedGoogle Scholar
• 45 Beuer K A, Conway E M, Bach R et al.. Tissue factor gene expression in acute myeloblastic leukemia.  Thromb Res. 1989;  56 425-430
  CrossrefPubMedGoogle Scholar
• 46 Beuer K A, Rosenberg R D. Thrombin generation in acute promyelocytic leukemia.  Blood. 1984;  64 791-796
  CrossrefPubMedGoogle Scholar
• 47 Myers T J, Rickles F R, Barb C, Cronlund M. Fibrinopeptide A in acute leukemia: relationship of activation of blood coagulation to disease activity.  Blood. 1981;  57 518-525
  CrossrefPubMedGoogle Scholar
• 48 Falanga A, Iacoviello L, Evangelista V et al.. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia given all-trans-retinoic acid.  Blood. 1995;  86 1072-1081
  PubMedGoogle Scholar
• 49 Bennett B, Booth A, Croll A, Dawson A A. The bleeding disorder in acute promyelocytic leukemia: fibrinolysis is due to u-PA rather than defibrination.  Br J Haematol. 1989;  71 511-517
  CrossrefPubMedGoogle Scholar
• 50 Dombret H, Scrobohaci M L, Ghorra P et al.. Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-trans retinoic acid treatment.  Leukemia. 1993;  7 2-9
  PubMedGoogle Scholar
• 51 Gralnick H R, Abrell E. Studies on the procoagulant and fibrinolytic activity of promyelocytes in acute promyelocytic leukemia.  Br J Haematol. 1973;  24 89-99
  CrossrefPubMedGoogle Scholar
• 52 Speiser W, Pabinger-Fasching I, Kyrle P A et al.. Hemostatic and fibrinolytic parameters in patients with acute myeloid leukemia: activation of blood coagulation, fibrinolysis and unspecific proteolysis.  Blut. 1990;  61 298-302
  PubMedGoogle Scholar
• 53 Tallman M S, Andersen J W, Schiffer C A et al.. All-trans retinoic acid in acute promyelocytic leukemia.  N Engl J Med. 1997;  337 1021-1028
  CrossrefPubMedGoogle Scholar
• 54 Mandelli F, Diverio D, Avvvisati G et al.. Molecular remission in PML/RaRalpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy.  Blood. 1997;  90 1014-1021
  PubMedGoogle Scholar
• 55 Runde V, Aul C, Heyll A, Schneider W. All-trans retinoic acid: not only a differentiating agent, but also an inducer of thromboembolic events in patients with M3 leukemia.  Blood. 1992;  79 534-535
  PubMedGoogle Scholar
• 56 Escudier S M, Kantarjian H M, Estey E H. Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid.  Leuk Lymphoma. 1996;  20 435-439
  CrossrefPubMedGoogle Scholar
• 57 Spruce W E, Forman S J, Blume K G et al.. Hemolytic uremic syndrome after bone marrow transplantation.  Acta Haematol. 1982;  67 206-210
  PubMedGoogle Scholar
• 58 Kondo M, Kojima S, Horibe K et al.. Hemolytic uremic syndrome after allogenic or autologous hemapoietic stem cell transplantation for childhood malignancies.  Bone Marrow Transplant. 1998;  21 281-286
  CrossrefPubMedGoogle Scholar
• 59 Pettitt A R, Clark R E. Thrombotic microangiopathy following bone marrow transplantation.  Bone Marrow Transplant. 1994;  14 495-504
  PubMedGoogle Scholar
• 60 Natazuka T, Kajimoto K, Ogawa R et al.. Coagulation abnormalities and thrombotic microangiopathy following bone marrow transplantation from HLA-matched unrelated donors in patients with hematological malignancies.  Bone Marrow Transplant. 1998;  21 815-819
  CrossrefPubMedGoogle Scholar
• 61 Moake J L, Rudy C K, Troll J H. Unusually large plasma factor VIII von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.  N Engl J Med. 1982;  307 1432-1436
  CrossrefPubMedGoogle Scholar
• 62 Chong B H, Murray B, Berndt M C et al.. Plasma P-selectin is increased in thrombotic consumptive platelet disorders.  Blood. 1994;  83 1535-1541
  CrossrefPubMedGoogle Scholar
• 63 Tsai H M. Molecular mechanisms in thrombotic thrombocytopenic purpura.  Semin Thromb Hemost. 2004;  30 549-557
  Article in Thieme ConnectPubMedGoogle Scholar
• 64 Kentouche K, Zintl F, Angerhaus D et al.. von Willebrand factor-cleaved protease (ADAMTS13) in the course of stem cell transplantation.  Semin Thromb Hemost. 2006;  32 98-104
  Article in Thieme ConnectPubMedGoogle Scholar
• 65 Wada H, Kaneko T, Ohiwa M et al.. Plasma cytokine levels in thrombotic thrombocytopenic purpura.  Am J Hematol. 1992;  40 167-170
  PubMedGoogle Scholar
• 66 Holler E, Kolb J H, Hiller F et al.. Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-vs-host-disease after HLA-identical bone marrow transplantation.  Blood. 1989;  73 2018-2024
  PubMedGoogle Scholar
• 67 Sarode R, McFarland J C, Flomemberg N et al.. Therapeutic plasma exchange does not appear to be effective in the management of TTP and hemolytic uremic syndrome following bone marrow transplantation.  Bone Marrow Transplant. 1995;  16 271-275
  PubMedGoogle Scholar
• 68 Hamblin N, Powles R, Treleaven J et al.. Defibrotide for refractory thrombotic thrombocytopenic purpura after bone marrow transplantation.  Blood. 1996;  88 2966 , (abst)
  PubMedGoogle Scholar
• 69 Bayik M M, Akoglu T, Tuglular T F et al.. Treatment of TTP with defibrotide.  Am J Hematol. 1993;  43 74-75
  CrossrefPubMedGoogle Scholar
• 70 Nosari A, Muti G, Busnach G et al.. Intravenous gamma globulin in refractory thrombotic thrombocytopenic purpura.  Acta Haematol. 1996;  96 255-257
  PubMedGoogle Scholar
• 71 Mohren M, Markmann I, Jentsch-Ullrich K et al.. Increased risk of venous thromboembolism in patients with acute leukaemia.  Br J Cancer. 2006;  94 200-202
  CrossrefPubMedGoogle Scholar
• 72 King M M, Rasnake M S, Rodriguez R G, Riley N J, Stamm J A. Peripherally inserted central venous catheter-associated thrombosis: retrospective analysis of clinical risk factors in adult patients.  South Med J. 2006;  99 1073-1077
  PubMedGoogle Scholar
• 73 Monreal M, Zotz R B, Decousus H et al.. Influence of perceived risk factors for bleeding on venous thromboembolism prophylaxis practices in acutely ill medical patients: findings from IMPROVE.  Blood. 2005;  106 269A , (abst)
  PubMedGoogle Scholar
• 74 Decousus H, Zotz R B, Tapson V F et al.. Factors at admission that are predictive of increased in-hospital bleeding in acutely ill medical patients: findings from the international medical prevention registry on venous thromboembolism (IMPROVE).  Blood. 2005;  106 81 , (abst)
  PubMedGoogle Scholar
• 75 Geerts W H, Pineo G F, Heit J A et al.. Prevention of venous thromboembolism.  Chest. 2004;  126 338S-400S
  CrossrefPubMedGoogle Scholar
• 76 Nicolaides A, Irving D, Pretzell M et al.. The risk of deep-vein thrombosis in surgical patients.  Br J Surg. 1973;  60 312
  PubMedGoogle Scholar
• 77 Flordal P A, Bergqvist D, Burmark U S et al.. Risk factors for major thromboembolism and bleeding tendency after elective general surgical operations.  Eur J Surg. 1996;  162 783-789
  PubMedGoogle Scholar
• 78 Enoxacan Study Group . Efficacy and safety of a low-molecular weight heparin and standard unfractionated heparin for prophylaxis of post-operative venous thromboembolism: European multicenter trial.  World J Surg. 1997;  21 2-8
  CrossrefPubMedGoogle Scholar
• 79 Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologic surgery.  N Engl J Med. 1988;  318 1162-1173
  CrossrefPubMedGoogle Scholar
• 80 Clagett G P, Reisch J S. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis.  Ann Surg. 1988;  208 227-240
  CrossrefPubMedGoogle Scholar
• 81 Mismetti P, Laporte S, Darmon J Y, Buchmuller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery.  Br J Surg. 2001;  88 913-930
  CrossrefPubMedGoogle Scholar
• 82 Bergqvist D, Burmark U S, Flordal P A et al.. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 units in 2070 patients.  Br J Surg. 1995;  82 496-501
  CrossrefPubMedGoogle Scholar
• 83 Wicky J, Couson F, Ambrosetti P et al.. Postoperative deep venous thrombosis (DVT) and low-molecular weight heparin (LMWH) type and dosage.  Thromb Haemost. 1993;  69 402-403
  PubMedGoogle Scholar
• 84 Wiig J N, Solhaug J H, Bilberg T et al.. Prophylaxis of venographically diagnosed deep vein thrombosis in gastro-intestinal surgery: multicentre trials 20mg and 40mg enoxaparin versus dextran.  Eur J Surg. 1995;  161 663-668
  PubMedGoogle Scholar
• 85 McLeod R S, Geerts W H, Sniderman K W et al.. Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the Canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial.  Ann Surg. 2001;  233 438-444
  CrossrefPubMedGoogle Scholar
• 86 Bjerkeset O, Larsen S, Reiertsen O. Evaluation of enoxaparin given before and after operation to prevent venous thromboembolism during digestive surgery: play-the-winner designed study.  World J Surg. 1997;  21 584-588
  CrossrefPubMedGoogle Scholar
• 87 Bergqvist D, Agnelli G, Cohen A T et al.. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.  N Engl J Med. 2002;  346 975-980
  CrossrefPubMedGoogle Scholar
• 88 Rasmussen M S. Preventing thromboembolic complications in cancer patients after surgery: a role for prolonged thromboprophylaxis.  Cancer Treat Rev. 2002;  28 141-144
  CrossrefPubMedGoogle Scholar
• 89 Rasmussen M S, Jorgensen L N, Willie-Jorgensen P et al.. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complication in patients undergoing major abdominal surgery: a multicenter randomised open-label study.  J Thromb Haemost. 2006;  4 2384-2390
  CrossrefPubMedGoogle Scholar
• 90 Nicolaides A, Fareed J, Kakkar A K et al.. Prevention and treatment of venous thromboembolism: International consensus statement.  Int Angiol. 2006;  25 101-161
  PubMedGoogle Scholar
• 91 Agnelli G, Bergqvist D, Cohen A, Gallus A, Gent M. for the PEGASUS investigators . Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk sbdominal surgery.  Br J Surg. 2005;  92 1212-1220
  CrossrefPubMedGoogle Scholar
• 92 Levine M, Hirsh J, Gent M et al.. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer.  Lancet. 1994;  343 886-889
  CrossrefPubMedGoogle Scholar
• 93 Samama M M, Cohen A T, Darmon J Y et al.. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.  N Engl J Med. 1999;  341 793-800
  CrossrefPubMedGoogle Scholar
• 94 Liezorovicz A, Cohen A T, Turpie A GG et al.. A randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in 3706 acutely ill medical patients: the PREVENT medical thromboprophylaxis study.  Thromb Haemost. 2003;  1(suppl) OC396 , (abst)
  PubMedGoogle Scholar
• 95 Cohen A T, Davidson B L, Gallus A S et al.. ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patient: randomized placebo controlled trial.  BMJ. 2006;  332 325-329
  CrossrefPubMedGoogle Scholar
• 96 Chong B H, Kakkar A K, Tapson V F et al.. Venous thromboembolism prophylaxis practices in acutely ill medical patients with either previous cancer or currently active cancer: findings from IMPROVE.  Blood. 2004;  104 490A , (abst)
  PubMedGoogle Scholar
• 97 Hutten B A, Prins M H, Gent M et al.. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis.  J Clin Oncol. 2000;  18 3078-3083
  PubMedGoogle Scholar
• 98 Koopman M M, Prandoni P, Piovella F et al.. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular weight heparin administered at home.  N Engl J Med. 1996;  334 682-687
  CrossrefPubMedGoogle Scholar
• 99 Columbus Investigators . Low-molecular weight heparin in the treatment of patients with venous thromboembolism.  N Engl J Med. 1997;  337 657-662
  CrossrefPubMedGoogle Scholar
• 100 Palareti G, Legnani C, Lee A et al.. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy.  Thromb Haemost. 2000;  84 805-810
  Article in Thieme ConnectPubMedGoogle Scholar
• 101 Prandoni P, Lensing A W, Picciolo A et al.. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.  Blood. 2002;  100 3484-3488
  CrossrefPubMedGoogle Scholar
• 102 Prandoni P. How I treat venous thromboembolism in patients with cancer.  Blood. 2005;  106 4027-4033
  CrossrefPubMedGoogle Scholar
• 103 Levine M, Gent M, Hirsh J et al.. A comparison of low-molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.  N Engl J Med. 1996;  334 677-681
  CrossrefPubMedGoogle Scholar
• 104 Kakkar A K, Levine M, Pinedo H M, Wolff R, Wong J. Venous thrombosis in cancer patients: insights from the FRONTLINE survey.  Oncologist. 2003;  8 381-388
  CrossrefPubMedGoogle Scholar
• 105 Ageno W, Steidl L, Marchesi C et al.. Selecting patients for home treatment of deep vein thrombosis: the problem of cancer.  Haematologica. 2002;  87 286-291
  PubMedGoogle Scholar
• 106 Chong B H, Brighton T A, Baker R, Thurlow P, Lee C H. Once-daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis.  J Thromb Thrombolysis. 2005;  19 173-181
  CrossrefPubMedGoogle Scholar
• 107 Merli G, Spiro T E, Olsson C G et al.. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.  Ann Intern Med. 2001;  134 191-202
  CrossrefPubMedGoogle Scholar
• 108 Simmoneau G, Sors H, Charbonnier B et al.. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group.  N Engl J Med. 1997;  337 663-669
  CrossrefPubMedGoogle Scholar
• 109 Kovacs M J, Anderson D, Morrow B et al.. Outpatient treatment of pulmonary embolism with dalteparin.  Thromb Haemost. 2000;  83 209-211
  PubMedGoogle Scholar
• 110 Buller H R, Davidson B L, Decousus H et al.. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.  Ann Intern Med. 2004;  140 867-873
  PubMedGoogle Scholar
• 111 Buller H R, Davidson B L, Decousus J et al.. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.  N Engl J Med. 2003;  349 1695-1702
  CrossrefPubMedGoogle Scholar
• 112 Marwan S, Akashes M S, Abu-Hajir M M. The safety of enoxaparin in patients older than 60 years with APL AML or high risk MDS undergoing induction or consolidation chemotherapy.  Blood. 1999;  94 225 , (abst 4211)
  PubMedGoogle Scholar
• 113 Imberti D, Vallisa D, Anselmi E et al.. Safety and efficacy of enoxaparin treatment in venous thromboembolic disease during acute leukemia.  Tumori. 2004;  90 390-393
  PubMedGoogle Scholar
• 114 Schimmer A D, Stewart A K, Keating A et al.. Safety of therapeutic anticoagulation in patients with multiple myeloma receiving autologous stem cell transplantation.  Bone Marrow Transplant. 1998;  22 491-494
  CrossrefPubMedGoogle Scholar
• 115 Levine M N, Lee A YY, Kakkar A K et al.. Cancer and thrombosis. In: Colman RC, Marder VJ, Clowes AW, George JN, Goldhaber SZ Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Philadelphia; Lippincott Williams & Wilkins 2006: 1251-1262
  Google Scholar
• 116 Decousus H, Leizorovicz A, Parent F et al.. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.  N Engl J Med. 1998;  338 409-415
  CrossrefPubMedGoogle Scholar
• 117 Millward S F, Oliva V L, Bell S D et al.. Gunther tulip retrievable vena cava filter: results from the registry of the Canadian Interventional Radiology Association.  J Vasc Interv Radiol. 2001;  12 1053-1058
  CrossrefPubMedGoogle Scholar
• 118 Meyer G, Marjanovic Z, Valcke J et al.. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study.  Arch Intern Med. 2002;  162 1729-1735
  CrossrefPubMedGoogle Scholar
• 119 Lee A Y, Levine M N, Baker R I et al.. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.  N Engl J Med. 2003;  349 146-153
  CrossrefPubMedGoogle Scholar
• 120 Scarpace S I, Hahn T, Roy H et al.. Arterial thrombosis in four patients treated with thalidomide.  Leuk Lymphoma. 2005;  46 239-242
  CrossrefPubMedGoogle Scholar

Beng H Chong

Level 2, Pitney Building, St. George Hospital

Gray St., Kogarah, New South Wales 2217, Australia

Email: beng.chong@unsw.edu.au